about
Cancer microRNAs: from subtype profiling to predictors of response to therapyNanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphomaMicroRNA signatures differentiate uterine cancer tumor subtypesA SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer riskSNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerMicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapyMicroRNA in cancer prognosisThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerCommon variants at 19p13 are associated with susceptibility to ovarian cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkersPrevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancerA polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.MicroRNA signatures differentiate melanoma subtypes.Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.MicroRNAs as potential cancer therapeutics.Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysisRadiation therapy oncology group gynecologic oncology working group: comprehensive resultsRibonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysisThe Holman Research Pathway in radiation oncology.miRNA modulation of the cellular stress response.microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.MicroRNA binding site polymorphisms as biomarkers of cancer risk.Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter.Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk.Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summaKRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer.The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
P50
Q24594739-5F2A690B-3830-46E3-BB2F-381F806BB7E0Q24595213-323033FA-737A-427A-92F0-61E1571220DCQ24633825-02C6A0C3-6D4C-47EB-94F9-046BB9555F23Q24655762-AB6FB5A2-2D86-4783-87C6-122ABBBD60DDQ26829794-F50DB6D8-25FB-4F38-94F8-EBD9F6B6B6D1Q28259779-F754080A-4293-4B5B-A58C-7C58CB4BA5AAQ28304380-14ACD044-DE38-416A-9345-6C2BE9B47B93Q28729202-F5CC19CC-8F3F-482A-877B-BEC9CADB23EDQ29417145-DA27EF1C-5759-49CB-9CA5-C0DAB0951FE4Q33640984-8C56DA70-B71A-495F-BB8E-9C878FC3E669Q33646928-EB937066-C74E-402E-B379-94256ACFAF7FQ33764182-E52BDB32-5B5D-410C-A462-2698E79A647BQ34030553-9F35E912-C6F5-4904-976A-74D513DE6FD3Q34072975-ADE6DD36-FAB2-44FF-B46F-F59CCDFA0F1CQ34182764-C6E503BC-F984-48F2-A09F-E9DCE28829D8Q34621039-2B002B94-C99A-463F-9DF5-E4B46C02F884Q35015730-0F8D8E6C-5342-4688-BBA9-CC957F32AB68Q35079572-92661FEF-69DA-46FE-B127-89BBC969584AQ35086711-6F198BBE-0237-4A41-A173-3F2109B5CBB4Q35097983-B9F55668-06DE-4FDA-A959-B3634F9E3A36Q35112046-EC64DFA5-3B0F-484A-BE1C-B361A76B0008Q35147597-A6479AFC-C9AC-4F62-94AF-E9A6A7E31440Q36335351-EA3F5D0C-5073-47A0-BAD3-D8A189538CF1Q36369415-9B7E95EA-325D-4727-9988-03073B07C25DQ36730351-C8DB849D-1F46-4240-ADF7-DED457F70A78Q36868936-9C25B0B2-89F9-411E-8000-ECF76A7107BDQ36916696-F2550F36-B3BC-4FA3-ADF9-D30C5A696B0FQ37137022-CBAEC7DC-AC32-4C13-9BE8-8FBDFD98B142Q37276128-9CC2BCD7-E758-45B1-9F9A-A0A33BC80FF8Q37320122-732105D0-49EF-4E37-BB11-A03E0061773BQ37365304-BAFC9446-B6FA-452A-9C37-F1EADB52E0E4Q37380005-AEFB6B34-0AC6-4FB3-85F2-FD3E7AEE1DFCQ37698895-E7F45455-6404-44CB-B8E3-DFBD40958FD4Q37833066-EBBB3160-9B2D-4F3B-A53F-F46881C14C09Q39312730-95688CA6-3606-4226-B879-667C3833A473Q39424345-010AAC38-B07F-4B59-B916-D024206F125BQ39452819-7435F541-5B7A-464F-8B76-CCA72DEC346FQ39608871-CB7AC6BA-7386-47CE-8556-741CB4D5D5E3Q39855685-06ECE359-D471-4DAF-91A1-D396F5D8FBB4Q43496062-FB19D611-D9D6-4FE6-874D-0DCA698F0A1F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joanne B Weidhaas
@nl
Joanne B Weidhaas
@sl
Joanne B. Weidhaas
@en
Joanne B. Weidhaas
@es
type
label
Joanne B Weidhaas
@nl
Joanne B Weidhaas
@sl
Joanne B. Weidhaas
@en
Joanne B. Weidhaas
@es
prefLabel
Joanne B Weidhaas
@nl
Joanne B Weidhaas
@sl
Joanne B. Weidhaas
@en
Joanne B. Weidhaas
@es
P106
P1153
14029423800
P21
P31
P496
0000-0002-5096-3281